» Articles » PMID: 27716346

Fundamentals of Aerosol Therapy in Critical Care

Overview
Journal Crit Care
Specialty Critical Care
Date 2016 Oct 8
PMID 27716346
Citations 36
Authors
Affiliations
Soon will be listed here.
Abstract

Drug dosing in critically ill patients is challenging due to the altered drug pharmacokinetics-pharmacodynamics associated with systemic therapies. For many drug therapies, there is potential to use the respiratory system as an alternative route for drug delivery. Aerosol drug delivery can provide many advantages over conventional therapy. Given that respiratory diseases are the commonest causes of critical illness, use of aerosol therapy to provide high local drug concentrations with minimal systemic side effects makes this route an attractive option. To date, limited evidence has restricted its wider application. The efficacy of aerosol drug therapy depends on drug-related factors (particle size, molecular weight), device factors, patient-related factors (airway anatomy, inhalation patterns) and mechanical ventilation-related factors (humidification, airway). This review identifies the relevant factors which require attention for optimization of aerosol drug delivery that can achieve better drug concentrations at the target sites and potentially improve clinical outcomes.

Citing Articles

Nanotechnology-based approaches for targeted drug delivery for the treatment of respiratory tract infections.

Georgakopoulou V, Papalexis P, Trakas N J Biol Methods. 2025; 11(4):e99010032.

PMID: 39839091 PMC: 11744063. DOI: 10.14440/jbm.2024.0065.


A Dynamic Breathing Lung Chip for Precise Evaluation of Inhaled Drug Efficacy and Airway Epithelial Responses.

Liu C, Chen Y, Mu H, Huang J ACS Biomater Sci Eng. 2024; 11(1):682-691.

PMID: 39616618 PMC: 11733924. DOI: 10.1021/acsbiomaterials.4c01377.


Aerosol Delivery With High-Frequency Assisted Airway Clearance Therapy in an Adult Airway and Lung Model: A Perfect Marriage?.

Gilmore T Respir Care. 2024; 69(10):1345-1346.

PMID: 39327027 PMC: 11469008. DOI: 10.4187/respcare.12428.


Nebuliser therapy in critical care: The past, present and future.

Arnott A, Watson M, Sim M J Intensive Care Soc. 2024; 25(1):78-88.

PMID: 39323591 PMC: 11421288. DOI: 10.1177/17511437231199899.


From mesenchymal stem cells to their extracellular vesicles: Progress and prospects for asthma therapy.

Chen S, Gao J, Zhang T Asian J Pharm Sci. 2024; 19(4):100942.

PMID: 39253613 PMC: 11382190. DOI: 10.1016/j.ajps.2024.100942.


References
1.
Pacheco J, Arnold H, Skrupky L, Watts P, Micek S, Kollef M . Predictors of outcome in 216 subjects with ARDS treated with inhaled epoprostenol. Respir Care. 2013; 59(8):1178-85. DOI: 10.4187/respcare.02939. View

2.
Holland A, Smith F, Penny K, McCrossan G, Veitch L, Nicholson C . Metered dose inhalers versus nebulizers for aerosol bronchodilator delivery for adult patients receiving mechanical ventilation in critical care units. Cochrane Database Syst Rev. 2013; (6):CD008863. PMC: 6516804. DOI: 10.1002/14651858.CD008863.pub2. View

3.
FINK J, Dhand R . Aerosol therapy in mechanically ventilated patients: recent advances and new techniques. Semin Respir Crit Care Med. 2005; 21(3):183-201. DOI: 10.1055/s-2000-9854. View

4.
Kermeen F, McNeil K, Fraser J, McCarthy J, Ziegenfuss M, Mullany D . Resolution of severe ischemia-reperfusion injury post-lung transplantation after administration of endobronchial surfactant. J Heart Lung Transplant. 2007; 26(8):850-6. DOI: 10.1016/j.healun.2007.05.016. View

5.
Wright T, Notter R, Wang Z, Harmsen A, Gigliotti F . Pulmonary inflammation disrupts surfactant function during Pneumocystis carinii pneumonia. Infect Immun. 2001; 69(2):758-64. PMC: 97949. DOI: 10.1128/IAI.69.2.758-764.2001. View